<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012165</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-AC-004</org_study_id>
    <nct_id>NCT03012165</nct_id>
  </id_info>
  <brief_title>A Study of ADX-102 in Subjects With Allergic Conjunctivitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the
      Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of
      ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CACÂ®) Model of Acute
      Allergic Conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching evaluated by the Subject.</measure>
    <time_frame>Efficacy assessment period (Day 3 through Day 15)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Ocular Itching Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular redness.</measure>
    <time_frame>Efficacy assessment period (Day 3 through Day 15)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Ocular Hyperemia Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tearing</measure>
    <time_frame>Efficacy assessment period (Day 3 through Day 15)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Tearing/Watery Eyes Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling</measure>
    <time_frame>Efficacy assessment period (Day 3 through Day 15)</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Eyelid Swelling Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>ADX-102 Ophthalmic Drops (0.5%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX-102 Ophthalmic Drops (0.1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of ADX-102 Ophthalmic Drops</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of ADX-102 Ophthalmic Drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 Ophthalmic Drops (0.5%)</intervention_name>
    <description>ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.</description>
    <arm_group_label>ADX-102 Ophthalmic Drops (0.5%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 Ophthalmic Drops (0.1%)</intervention_name>
    <description>ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.</description>
    <arm_group_label>ADX-102 Ophthalmic Drops (0.1%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of ADX-102 Ophthalmic Drops</intervention_name>
    <description>Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.</description>
    <arm_group_label>Vehicle of ADX-102 Ophthalmic Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be at least 18 years of age of either gender and any race

          -  have a positive history of ocular allergies and a positive skin test reaction to a
             seasonal (grasses, ragweed, and/or trees) or perennial allergen (cat dander, dog
             dander, dust mites, cockroach) as confirmed by an allergic skin test within the past
             24 months

          -  have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using
             an ETDRS chart

        Exclusion Criteria:

          -  have known contraindications or sensitivities to the use of the investigational
             product or any of its components

          -  have any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters (including but not limited to narrow angle
             glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis,
             pterygium or a diagnosis of dry eye)

          -  have had ocular surgical intervention within three (3) months prior to Visit 1 or
             during the study and/or a history of refractive surgery within the past six (6)
             months

          -  have a known history of retinal detachment, diabetic retinopathy, or active retinal
             disease

          -  have the presence of an active ocular infection (bacterial, viral or fungal) or
             positive history of an ocular herpetic infection at any visit

          -  be a female who is currently pregnant, planning a pregnancy, lactating, not using a
             medically acceptable form of birth control throughout the study duration and for 14
             days prior to the installation of investigational product, or has a positive urine
             pregnancy test at Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>December 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADX-102</keyword>
  <keyword>Allergic Conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
